Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Claims Lead In New Pain Management Compound; Files For Multiple Patents

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Inspired by major out-licensing deals with companies including Eli Lilly and more recently Sanofi-Aventis for research in pain management drugs in the transient receptor potential (TRP) class, India's Glenmark Pharmaceuticals has beefed up its presence in this category by announcing discovery of yet another novel chemical entity, coded GRC 17536
Advertisement

Related Content

Glenmark’s Pain Drug Fails To Meet Primary Endpoint, Path Of Another Altered By Sanofi
"We Have Gone Through Hardships But Our Passion Remains High," Says Glenn Saldanha, Managing Director, Glenmark Pharma: An Interview With PharmAsia News (Part 2 of 2)
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities
Advertisement
UsernamePublicRestriction

Register

SC075795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel